Etokimab (I-Mab Biopharma), which is optimized for common IL-33 gene polymorphisms, has completed patient recruitment in its ...

That said, etokimab will continue to lead the pipeline, and the latest interim data from the phase 2a study in eosinophilic asthma have given investors something to cheer about following the ...

Next-generation antibody company AnaptysBio has positive data for its lead pipeline drug etokimab in a third indication, adding asthma to its earlier wins in peanut allergy and atopic dermatitis ...

What happened Shares of AnaptysBio (NASDAQ: ANAB) rose more than 12% last month, according to data provided by S&P Global Market Intelligence ..

The oral presentation, titled “Single-Dose Phase 2a Trial of Etokimab (anti-IL-33) in Severe Eosinophilic Asthma”, was presented by Dr. Marco Londei, AnaptysBio’s Chief Medical Officer, and ...

AnaptysBio's asthma study looks promising. The company's atopic dermatitis study is progressing. ... the company will report for additional readouts from its ongoing trials of ANB019 and etokimab.

AnaptysBio fell in sympathy with Regeneron's drug REGN3500 not being any better than Dupixent. While it is still risky in that etokimab could end up not generating enough sales for asthma, it is ...

The biopharma announced positive top-line data from a phase 2a trial involving its lead drug candidate as a treatment for asthma.

Equally important to effectively improving the quality of life of asthma patients is the fact that etokimab didn't cause any serious adverse events, which bolsters its safety profile. Other ...

Shares of AnaptysBio (NASDAQ: ANAB) rose over 18% after the company announced positive top-line data from an ongoing phase 2a trial investigating the potential of its lead drug candidate to treat ...

Equally important to effectively improving the quality of life of asthma patients is the fact that etokimab didn't cause any serious adverse events, which bolsters its safety profile. Other ...

What happened Shares of AnaptysBio (NASDAQ: ANAB) rose over 18% after the company announced positive top-line data from an ongoing phase 2a trial.